For Q3 FY2025 (period ended September 30, 2025), Zenas BioPharma reported no revenue and a net loss of $80.99 million, compared to a loss of $33.56 million in the prior year quarter. Operating loss was $77.35 million, and diluted EPS was -$1.46.
•Revenue was $0 for the quarter.
•Net loss widened to $80.99 million from $33.56 million year-over-year.
•Operating loss was $77.35 million.
•Diluted EPS was -$1.46.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Zenas BioPharma, Inc., a clinical-stage biopharma company provides the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company develops ZB002, an anti-TNFa monoclonal antibody. Its portfolio also includes ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus, and ZB001, an anti-IGF-1R monoclonal antibody. Incorporated in 2019 and headquartered in Waltham, Massachusetts, the company was formerly known as Zenas BioPharma (Cayman) Limited before rebranding in August 2023.
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb, targeting immune and inflammatory (I&I) diseases such as immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein engineered for extended half-life; and ZB001, an anti-IGF-1R monoclonal antibody. These candidates address various autoimmune and inflammatory conditions.
Where is Zenas BioPharma (ZBIO) listed and what currency does it trade in?
Zenas BioPharma is listed on the Nasdaq Global Select Market under the ticker symbol ZBIO. Its shares trade in US Dollars (USD). The company is headquartered in Waltham, Massachusetts, United States, and its stock is accessible to investors through major US brokerage platforms.
What sector and industry does Zenas BioPharma (ZBIO) belong to?
Zenas BioPharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing novel therapies for immune and inflammatory diseases, which is a core area of biotechnology. The company's pipeline includes monoclonal antibodies and fusion proteins designed to modulate the immune system.
Where is Zenas BioPharma (ZBIO) headquartered and what is its history?
Zenas BioPharma is headquartered in Waltham, Massachusetts, United States. The company was incorporated in 2019 and was formerly known as Zenas BioPharma (Cayman) Limited before rebranding to its current name in August 2023. Its operations are based in the US, and it focuses on developing immunology-based therapies for global markets.
What are the key product candidates in Zenas BioPharma's (ZBIO) pipeline?
Zenas BioPharma's pipeline includes several notable product candidates. Its lead candidate is obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb for autoimmune diseases like IgG4-related disease, multiple sclerosis, and lupus. Additionally, ZB002 is an anti-TNFα monoclonal antibody for inflammatory conditions. ZB004 is a CTLA-4-Ig fusion protein designed for extended half-life, and ZB001 is an anti-IGF-1R monoclonal antibody. These candidates are in various stages of clinical development.